Efter et år fik patienter behandlet med Tysabri ca. to tredjedele færre MS- anfald end patienter, der fik placebo.
After one year, there was a decrease of about two-thirds in the number of MS attacks in Tysabri-treated patients, in comparison with the patients who received placebo.